INMB
INMB
NASDAQ · Biotechnology

Inmune Bio Inc

$1.51
+0.09 (+6.34%)
As of Feb 8, 2:20 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 12.17M 11.20M 11.67M
Net Income 1.39M 1.78M 1.44M
EPS
Profit Margin 11.4% 15.9% 12.3%
Rev Growth +22.0% +3.1% +2.1%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 15.00M 11.90M 13.58M
Total Equity 28.79M 32.54M 29.49M
D/E Ratio 0.52 0.37 0.46
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 2.67M 2.32M 2.58M
Free Cash Flow 1.15M 977.1K 708.5K